Abstract 2888: Tumor-targeted CD28 bispecific POWERbody࣪ for safe and synergistic T cell-mediated immunotherapy

Autor: Guizhong Liu, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Bin Cai, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Yan Li, Felix Du, Peter Luo

Publikováno v: Cancer Research. 82:2888-2888

Targeting CD28 for systemic T cell activation caused severe cytokine storm and multiorgan failure in an anti-CD28 antibody TGN1412 phase 1 trial. However, tumor specific CD28 targeting in a tumor associated antigen (TAA)×CD28 bispecific format, simi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af9e05fd14f8808636aab233c1177071
https://doi.org/10.1158/1538-7445.am2022-2888

Abstract 4257: ADG153-G1, a highly differentiated anti-CD47 IgG1 SAFEbody, demonstrates potent in vivo anti-tumor activities with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities

Autor: Bin Cai, Aaron N. Nguyen, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Peter Luo, Jiangchun Xu

Publikováno v: Cancer Research. 82:4257-4257

Anti-CD47 antibodies of the IgG4 isotype have shown promising activities in clinical trials for hematologic malignancies, mainly in the combination setting. To overcome the fundamental challenge of developing an anti-CD47 antibody of an active Fc iso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56ae6dcd030f11fe62c816a4cbc2f4f6
https://doi.org/10.1158/1538-7445.am2022-4257

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Autor: Paul W Hollenbach, Aaron N Nguyen, Helen Brady, Michelle Williams, Yuhong Ning, Normand Richard, Leslie Krushel, Sharon L Aukerman, Carla Heise, Kyle J MacBeth

Publikováno v: PLoS ONE, Vol 5, Iss 2, p e9001 (2010)

BACKGROUND: The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). Few non-clinical studies have directly compared the mechanisms

Externí odkaz: https://doaj.org/article/80331f59b43f47a1b73c70859de811dc

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Autor: Aaron N. Nguyen, Johanna C. Bendell, Patricia LoRusso, Christophe Le Tourneau, Miguel Martin, Drew W. Rasco, W. Jeff Edenfield, Pamela N. Munster, Jose A. Lopez-Martin, Bert H. O'Neil, Gordon L. Bray, Elisabeth I. Heath, Eric Laille, Jorge DiMartino, Kejian Liu, Jan H.M. Schellens, Nicolas Isambert, Daniel D. Von Hoff, Ron H.J. Mathijssen

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 17
Clinical Cancer Research, 24(17), 4072-4080. American Association for Cancer Research Inc.
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (17), pp.4072-4080. ⟨10.1158/1078-0432.CCR-17-3716⟩

Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cecb67cd7b46e1fc948f8af0c2ef502
https://escholarship.org/uc/item/95c380xz

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Autor: Leonidas C. Platanias, Josh Hayman, Satyanarayana Medicherla, Linda S. Higgins, Jing Ying Ma, Bhaskar Das, Andrea Pellagatti, Perry Pahanish, Krishna Gundabolu, Markus Bitzer, Ying Zhang, Tony A. Navas, Davendra Sohal, Aaron N. Nguyen, Amittha Wickrema, Alan F. List, Suman Kambhampati, Adam Chubak, Tushar D. Bhagat, Simrit Parmar, Ira Braunchweig, Amit Verma, Li Zhou, Jacqueline Boultwood, Yongkai Mo, Ann M. Kapoun

Publikováno v: Blood. 112:3434-3443

MDS is characterized by ineffective hematopoiesis that leads to peripheral cytopenias. Development of effective treatments has been impeded by limited insight into pathogenic pathways governing dysplastic growth of hematopoietic progenitors. We demon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9e6b227c8bd1b45cd01fc960e45434
https://doi.org/10.1182/blood-2008-02-139824